Home/Filings/4/0001301120-26-000004
4//SEC Filing

Moreadith Randall 4

Accession 0001301120-26-000004

CIK 0001708599other

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 12:56 PM ET

Size

13.4 KB

Accession

0001301120-26-000004

Insider Transaction Report

Form 4
Period: 2026-01-13
Moreadith Randall
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-13$0.06/sh+5,416$3255,416 total
  • Sale

    Common Stock

    2026-01-13$2.50/sh5,416$13,5400 total
  • Exercise/Conversion

    Common Stock

    2026-01-14$0.06/sh+1,084$651,084 total
  • Sale

    Common Stock

    [F1]
    2026-01-14$2.50/sh1,084$2,7130 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F2]
    2026-01-135,416333,770 total
    Exercise: $0.06Exp: 2031-05-06Common Stock (5,416 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    [F2]
    2026-01-141,084332,686 total
    Exercise: $0.06Exp: 2031-05-06Common Stock (1,084 underlying)
Footnotes (2)
  • [F1]The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.50. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F2]The stock options are fully vested.
Signature
/s/ Randall Moreadith|2026-01-14

Issuer

Serina Therapeutics, Inc.

CIK 0001708599

Entity typeother

Related Parties

1
  • filerCIK 0001301120

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 12:56 PM ET
Size
13.4 KB